Physician profile
William Quayle
NPI 1144215336
$1,459.12
in general payments reported to CMS, 2019-2025
20 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $170 · 2021: $250 · 2022: $118 · 2023: $109 · 2024: $220 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $298.94 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $188.02 | 2019-2025 | Cequa |
| Alcon Vision LLC | $136.73 | 2021-2025 | Clareon, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $125.84 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $110.77 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Abbvie INC. | $94.22 | 2024-2025 | |
| Allergan, INC. | $74.41 | 2020-2022 | |
| Oyster Point Pharma, INC. | $56.06 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $50.59 | 2024-2025 | Vevye |
| Dompe US, INC. | $33.29 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $23.98 | 2022 | |
| Shire North American Group INC | $21.66 | 2019 | |
| Astellas Pharma US INC | $18.47 | 2024 | Izervay |
| Akorn Operating Company LLC | $17.70 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.18 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $14.97 | 2021 | |
| Sight Sciences, INC. | $14.69 | 2022 | |
| Ocular Therapeutix, INC. | $14.64 | 2021 | |
| Biotissue Holdings INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Quayle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.